Bavarian Nordic Aims To Advance Early-Stage Pipeline With Funds From Bristol Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
By buying an option to license and commercialize Bavarian Nordic’s Prostvac, Bristol-Myers Squibb will be validating the drug’s underlying technology and providing the Danish biotech needed cash to progress its remaining pipeline.